DOP2003000765A - Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease - Google Patents

Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease

Info

Publication number
DOP2003000765A
DOP2003000765A DO2003000765A DO2003000765A DOP2003000765A DO P2003000765 A DOP2003000765 A DO P2003000765A DO 2003000765 A DO2003000765 A DO 2003000765A DO 2003000765 A DO2003000765 A DO 2003000765A DO P2003000765 A DOP2003000765 A DO P2003000765A
Authority
DO
Dominican Republic
Prior art keywords
useful
treatment
alzheimer
disease
carbamates
Prior art date
Application number
DO2003000765A
Other languages
English (en)
Inventor
Shon R Pulley
John A Tucker
Original Assignee
Elan Fharmaceuticals Inc
Pharmacia Y Up John Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32469374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2003000765(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Fharmaceuticals Inc, Pharmacia Y Up John Company filed Critical Elan Fharmaceuticals Inc
Publication of DOP2003000765A publication Critical patent/DOP2003000765A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

la invencion brinda compuestos de fómula 1 útiles para el tratamiento de alzhimer y otras enfermedades similares. los compuestos incluyen inhividores de la enzima beta-secretasa que son útiles para el tratamiento de la enfermedad de alzheimer y otras enfermedades caracterizadas por depósito de péptidos a beta en un mamifero. los compuestos de la invención son útiles en compociciones farmacéuticas y métodos de tratamiento para reducir la formación de péptido
DO2003000765A 2002-11-27 2003-11-26 Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease DOP2003000765A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42976902P 2002-11-27 2002-11-27

Publications (1)

Publication Number Publication Date
DOP2003000765A true DOP2003000765A (es) 2004-05-31

Family

ID=32469374

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2003000765A DOP2003000765A (es) 2002-11-27 2003-11-26 Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease

Country Status (14)

Country Link
US (2) US7351738B2 (es)
EP (1) EP1565428A1 (es)
JP (1) JP2006508166A (es)
AR (1) AR043062A1 (es)
AU (1) AU2003293155A1 (es)
BR (1) BR0316629A (es)
CA (1) CA2507484A1 (es)
DO (1) DOP2003000765A (es)
MX (1) MXPA05005649A (es)
PA (1) PA8589701A1 (es)
PE (1) PE20040762A1 (es)
TW (1) TW200505828A (es)
UY (1) UY28101A1 (es)
WO (1) WO2004050609A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7291744B2 (en) * 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005070407A1 (en) * 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
JP2007528404A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
WO2005087714A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
JP2007528400A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US20060128715A1 (en) * 2004-07-09 2006-06-15 Jennifer Sealy Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
WO2006010095A2 (en) 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
AU2005286844A1 (en) * 2004-09-17 2006-03-30 Comentis, Inc Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
NZ562314A (en) * 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
AU2006278713A1 (en) * 2005-08-03 2007-02-15 Merck & Co., Inc. Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
US7816387B2 (en) 2005-09-05 2010-10-19 Dainippon Sumitomo Pharma Co., Ltd. β secretase inhibitor
EP1937638A1 (en) * 2005-10-12 2008-07-02 Elan Pharmaceuticals Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007061670A1 (en) * 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
WO2008137954A2 (en) * 2007-05-07 2008-11-13 Environmental Packaging Technologies Limited Universal shipping container
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US20100286145A1 (en) * 2007-07-26 2010-11-11 Comentis, Inc. Isophthalamide derivatives inhibiting beta-secretase activity
WO2009129532A1 (en) * 2008-04-18 2009-10-22 University Of Connecticut Compounds for lysosomal modulation and methods of use
US11040947B2 (en) 2017-03-22 2021-06-22 The Research Foundation For The State University Of New York Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6133152A (ja) * 1984-06-22 1986-02-17 アボツト　ラボラトリ−ズ リ−ニン阻害化合物
EP0190891A3 (en) * 1985-01-31 1988-04-20 Kissei Pharmaceutical Co. Ltd. Novel amino acid derivatives
US4665055A (en) * 1985-06-17 1987-05-12 Merck & Co., Inc. Peptide renin inhibitors
US5175281A (en) 1985-09-12 1992-12-29 The Upjohn Company Pharmaceutically active pyrimidinylpiperazinylsterioids
CA1297631C (en) * 1985-12-23 1992-03-17 Sesha I. Natarajan Ureido renin inhibitors
US4864017A (en) 1986-09-05 1989-09-05 The Upjohn Company Novel renin inhibiting peptides having a dihyroxyethylene isostere transition state insert
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
WO1992008701A1 (en) * 1990-11-19 1992-05-29 Monsanto Company Retroviral protease inhibitors
ES2236682T5 (es) 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993001166A1 (en) * 1991-07-02 1993-01-21 Sandoz Ltd. 4-amino-3-hydroxycarboxylic acid derivatives
AU671093B2 (en) 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
RU2146668C1 (ru) * 1992-08-25 2000-03-20 Джи Ди Сирл энд Компани Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидное соединение, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
ATE201197T1 (de) * 1994-07-07 2001-06-15 Pharmeco Lab Inc Diarinopropanole abgeleitet von aminosäuren
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH09124629A (ja) * 1995-10-26 1997-05-13 Kissei Pharmaceut Co Ltd カルバミン酸テトラヒドロフリルエステル誘導体の製造方法
WO1998022597A2 (en) 1996-11-20 1998-05-28 Oklahoma Medical Research Foundation Cloning and characterization of napsin, an aspartic protease
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2000003819A1 (en) 1998-07-17 2000-01-27 The Penn State Research Foundation Full form roll finishing technique
PL205294B1 (pl) 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
GB2364059B (en) 1999-02-10 2004-01-14 Elan Pharm Inc Beta-Secretase enzyme compositions and methods
JP4814427B2 (ja) * 1999-02-12 2011-11-16 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼのインヒビター
JP2003502342A (ja) 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤
WO2001023533A2 (en) 1999-09-23 2001-04-05 Pharmacia & Upjohn Company Alzheimer's disease secretase, app substrates therefor, and uses therefor
GB0012795D0 (en) * 2000-05-25 2000-07-19 Novartis Ag Organic compounds
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
JP2004502664A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
AU2001281250A1 (en) * 2000-08-11 2002-02-25 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
MXPA03011046A (es) * 2001-06-01 2004-06-25 Elan Pharm Inc Hidroxialquilaminas.
CN101068772A (zh) * 2001-07-11 2007-11-07 艾伦药物公司 N－(3－氨基－2－羟基－丙基)取代烷基酰胺化合物
AU2002359376B2 (en) * 2001-11-08 2008-01-10 Elan Pharmaceuticals, Inc. N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
AU2002360508A1 (en) * 2001-12-06 2003-06-23 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
KR20050032025A (ko) * 2002-02-27 2005-04-06 엘란 파마슈티칼스, 인크. 치환된 히드록시에틸아민
WO2003091264A2 (en) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
EA008389B1 (ru) * 2002-06-20 2007-04-27 Фармация Энд Апджон Компани Ллс Способ получения производных 5-(1,3-оксазол-2-ил)бензойной кислоты
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
CA2497979A1 (en) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
ATE443043T1 (de) * 2002-11-12 2009-10-15 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
KR100793095B1 (ko) * 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US7291744B2 (en) * 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
AR043062A1 (es) 2005-07-13
TW200505828A (en) 2005-02-16
AU2003293155A1 (en) 2004-06-23
PE20040762A1 (es) 2004-11-06
EP1565428A1 (en) 2005-08-24
US20080306136A1 (en) 2008-12-11
WO2004050609A8 (en) 2005-07-21
MXPA05005649A (es) 2005-08-16
UY28101A1 (es) 2004-06-30
WO2004050609A1 (en) 2004-06-17
US7351738B2 (en) 2008-04-01
BR0316629A (pt) 2005-10-11
CA2507484A1 (en) 2004-06-17
US20040209925A1 (en) 2004-10-21
PA8589701A1 (es) 2004-11-26
JP2006508166A (ja) 2006-03-09
AU2003293155A8 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
DOP2003000765A (es) Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
GT200400076A (es) Ligandos de receptores de cannabinoides y sus usos
UY27967A1 (es) Acetil 2-hindroxi-1,3-diaminoalcanos
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
BR0306724A (pt) carboxamidas amino substituìdas para tratamento de doença de alzheimer
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
MXPA04003245A (es) Hidroxipropilaminas.
CR7436A (es) Hidroxietilaminas substituidas
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
DE60210614D1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
ATE534736T1 (de) Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
SV2005001840A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - docket 17005
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
BR0314714A (pt) Compostos para o tratamento da doença de alzheimer
ES2284970T3 (es) Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer.
CR7720A (es) Acetil 2-hidroxi-1,3- diaminoalcanos
PA8601101A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
DOP2004000889A (es) Fenacilo 2-hidroxi-3-diaminoalcanos (phenacyl 2-hydroxy-3-diaminoalkanes)
BR0317445A (pt) Composto, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
ECSP044940A (es) N-(3-amino-2-hidroxil-propil) compuestos substitutos de alquilamida